Millennium Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Millennium Management’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-558	Closed	-$8.38K	–	6684
2023 Q3	$8.38K	Buy	558 +18	+3%	+$313	﹤0.01%	5790
2023 Q2	$11.2K	Buy	+540	New	+$9.12K	﹤0.01%	5742
2023 Q1	–	Sell	-844	Closed	-$9K	–	7044
2022 Q4	$9K	Buy	844 +202	+31%	+$2.56K	﹤0.01%	6212
2022 Q3	$9K	Buy	+642	New	+$12.6K	﹤0.01%	6691
2021 Q3	–	Sell	-10,295	Closed	-$2.54M	–	7380
2021 Q2	$2.54M	Buy	+10,295	New	+$2.53M	﹤0.01%	3656

Other funds holding EFTR

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SIMG

Sonora Investment Management Group Tucson, Arizona $1.41B AUM 20.58% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management's EFTR Position: Q4 2023 in Review

Millennium Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2023, closing a stake of 558 shares — an estimated $8.38K sold.

Millennium Management first reported a position in EFTR in Q2 2021 and held it in 5 quarters. The position peaked at $2.54M in Q2 2021. 25 funds tracked by Wall St. Rank hold EFTR as of Q4 2023.

Millennium Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Millennium Management sold 558 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $8.38K.
Millennium Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Millennium Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $2.54M in Q2 2021.
25 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.